- Home
- MAIA vs MIST Comparison
MAIA vs MIST Comparison
Compare MAIA & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MAIA
- MIST
- Stock Information
- Founded
- MAIA 2018
- MIST 2003
- Country
- MAIA United States
- MIST Canada
- Employees
- MAIA N/A
- MIST N/A
- Industry
- MAIA Biotechnology: Pharmaceutical Preparations
- MIST Biotechnology: Pharmaceutical Preparations
- Sector
- MAIA Health Care
- MIST Health Care
- Exchange
- MAIA Nasdaq
- MIST Nasdaq
- Market Cap
- MAIA 62.4M
- MIST 81.5M
- IPO Year
- MAIA 2022
- MIST N/A
- Fundamental
- Price
- MAIA $2.82
- MIST $1.43
- Analyst Decision
- MAIA
- MIST Strong Buy
- Analyst Count
- MAIA 0
- MIST 3
- Target Price
- MAIA N/A
- MIST $13.00
- AVG Volume (30 Days)
- MAIA 60.0K
- MIST 177.8K
- Earning Date
- MAIA 11-05-2024
- MIST 11-11-2024
- Dividend Yield
- MAIA N/A
- MIST N/A
- EPS Growth
- MAIA N/A
- MIST N/A
- EPS
- MAIA N/A
- MIST N/A
- Revenue
- MAIA N/A
- MIST N/A
- Revenue This Year
- MAIA N/A
- MIST N/A
- Revenue Next Year
- MAIA N/A
- MIST N/A
- P/E Ratio
- MAIA N/A
- MIST N/A
- Revenue Growth
- MAIA N/A
- MIST N/A
- 52 Week Low
- MAIA $0.82
- MIST $1.12
- 52 Week High
- MAIA $5.99
- MIST $3.52
- Technical
- Relative Strength Index (RSI)
- MAIA 50.98
- MIST 42.50
- Support Level
- MAIA $2.36
- MIST $1.41
- Resistance Level
- MAIA $2.72
- MIST $1.53
- Average True Range (ATR)
- MAIA 0.22
- MIST 0.07
- MACD
- MAIA 0.02
- MIST -0.01
- Stochastic Oscillator
- MAIA 72.28
- MIST 26.96
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company. The company develops targeted immunotherapies for cancer. The company is an immune-oncology company, focused on the development of first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. The company's program is THIO, a potential cancer telomere-targeting agent in clinical development for the treatment of telomerase-positive cancer cells.
About MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to terminate episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).